Recent News

• 11.24.2025 - Ultragenyx to Participate in Investor Conferences in December
• 11.21.2025 - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 11.04.2025 - Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update
• 11.04.2025 - Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences
• 10.30.2025 - Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups
• 10.28.2025 - Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update
• 10.24.2025 - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 10.08.2025 - Ultragenyx annuncia l'approvazione da parte dell'AIFA (Agenzia Italiana del Farmaco) del rimborso di Evkeeza® (evinacumab) per i pazienti pediatrici di età pari a 6 mesi con ipercolesterolemia familiare omozigote (HoFH)
• 10.03.2025 - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 10.03.2025 - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 11.05.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.05.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.04.2025 - EX-99.1 EX-99.1
• 11.04.2025 - 8-K Current report
• 10.30.2025 - 8-K Current report
• 10.14.2025 - 4 Statement of changes in beneficial ownership of securities